[go: up one dir, main page]

IT1283951B1 - Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di - Google Patents

Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di

Info

Publication number
IT1283951B1
IT1283951B1 IT96RM000171A ITRM960171A IT1283951B1 IT 1283951 B1 IT1283951 B1 IT 1283951B1 IT 96RM000171 A IT96RM000171 A IT 96RM000171A IT RM960171 A ITRM960171 A IT RM960171A IT 1283951 B1 IT1283951 B1 IT 1283951B1
Authority
IT
Italy
Prior art keywords
carnitine
prophylaxis
acetyl
acceptable salts
pharmacologically acceptable
Prior art date
Application number
IT96RM000171A
Other languages
English (en)
Inventor
Sonia Moretti
Original Assignee
Mendes Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendes Srl filed Critical Mendes Srl
Publication of ITRM960171A0 publication Critical patent/ITRM960171A0/it
Priority to IT96RM000171A priority Critical patent/IT1283951B1/it
Priority to TW086102934A priority patent/TW513304B/zh
Priority to CA002248879A priority patent/CA2248879A1/en
Priority to EP97907268A priority patent/EP0888113A1/en
Priority to US09/147,034 priority patent/US6037372A/en
Priority to PCT/IT1997/000056 priority patent/WO1997034596A1/en
Priority to KR10-1998-0707309A priority patent/KR100481188B1/ko
Priority to JP53332497A priority patent/JP2001503731A/ja
Priority to ZA9702219A priority patent/ZA972219B/xx
Publication of ITRM960171A1 publication Critical patent/ITRM960171A1/it
Application granted granted Critical
Publication of IT1283951B1 publication Critical patent/IT1283951B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT96RM000171A 1996-03-15 1996-03-15 Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di IT1283951B1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT96RM000171A IT1283951B1 (it) 1996-03-15 1996-03-15 Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
TW086102934A TW513304B (en) 1996-03-15 1997-03-10 Use of an alkanoyl L-carnitine or a pharmacologically acceptable salt thereof for the therapeutic treatment or prophylaxis of glutamate-mediated disturbances or diseases
US09/147,034 US6037372A (en) 1996-03-15 1997-03-12 Use of an alkanoyl-L-carnitine for the treatment of glutamate mediated diseases
EP97907268A EP0888113A1 (en) 1996-03-15 1997-03-12 Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases
CA002248879A CA2248879A1 (en) 1996-03-15 1997-03-12 Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases
PCT/IT1997/000056 WO1997034596A1 (en) 1996-03-15 1997-03-12 Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases
KR10-1998-0707309A KR100481188B1 (ko) 1996-03-15 1997-03-12 글루타민산염관련질환치료용알카노일-l-카르니틴의용도
JP53332497A JP2001503731A (ja) 1996-03-15 1997-03-12 グルタメート仲介疾患の処置のためアルカノイル―ｌ―カルニチンの使用
ZA9702219A ZA972219B (en) 1996-03-15 1997-03-14 Alkanoyl L-carnitine composition against glutamate-mediated conditions.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000171A IT1283951B1 (it) 1996-03-15 1996-03-15 Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di

Publications (3)

Publication Number Publication Date
ITRM960171A0 ITRM960171A0 (it) 1996-03-15
ITRM960171A1 ITRM960171A1 (it) 1997-09-15
IT1283951B1 true IT1283951B1 (it) 1998-05-07

Family

ID=11403995

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96RM000171A IT1283951B1 (it) 1996-03-15 1996-03-15 Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di

Country Status (9)

Country Link
US (1) US6037372A (it)
EP (1) EP0888113A1 (it)
JP (1) JP2001503731A (it)
KR (1) KR100481188B1 (it)
CA (1) CA2248879A1 (it)
IT (1) IT1283951B1 (it)
TW (1) TW513304B (it)
WO (1) WO1997034596A1 (it)
ZA (1) ZA972219B (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277897B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
IT1299161B1 (it) * 1998-04-17 2000-02-29 Sigma Tau Healthscience Spa Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
AU1294600A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
CA2352485A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20120093809A1 (en) * 2008-12-01 2012-04-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2586438A1 (en) 2011-10-28 2013-05-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is in treatment with azidothymidine
CN114522158B (zh) * 2022-01-21 2023-06-27 武汉大学 用于制备治疗肝癌药物的代谢物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
AU6922994A (en) * 1993-06-21 1995-01-17 Bernardini, Attilio Use of acylcarnitin to treat illnesses caused by aids

Also Published As

Publication number Publication date
TW513304B (en) 2002-12-11
ITRM960171A0 (it) 1996-03-15
KR100481188B1 (ko) 2005-07-07
CA2248879A1 (en) 1997-09-25
JP2001503731A (ja) 2001-03-21
US6037372A (en) 2000-03-14
WO1997034596A1 (en) 1997-09-25
ZA972219B (en) 1997-09-17
EP0888113A1 (en) 1999-01-07
ITRM960171A1 (it) 1997-09-15
KR20000064614A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
IT1283951B1 (it) Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
ITMI941693A0 (it) Sali organici idrosolubili della creatina
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
EE04190B1 (et) Asendatud bensopüraani derivaatide kasutamine põletiku raviks
EP0902665A4 (en) NUTRITIONAL PHYTO-ESTROGENES IN ESTRO-REPLACEMENT THERAPY
EP1089751A4 (en) Adjuvant therapy
IT1302365B1 (it) Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
ITRM950545A0 (it) Uso di amminoacidi basici di acil derivati di amminoacidi basi e di loro sali farmaceuticamente accettabili per la profilassi di malattieo per il trattamento terapeutico di disturbi citologici associati a livelli elevati di ceramide
ITRM910363A1 (it) Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
ITMI950566A0 (it) Procedimento per la preparazione di antibiotici della classe delle antracicline
PT1231915E (pt) Uso de derivados de pleuromutilina para tratamento transdermal de doencas bacterianas
ITMI910456A0 (it) Composizione farmaceutica per il trattamento della cataratta
ITMI931700A0 (it) Procedimento per la potabilizzazione delle acque destinate al consumo umano
ITPD920145A0 (it) Uso terapeutico della fosforil-serina-n-acil-sfingosina
ITMI950958A0 (it) Composizioni farmaceutiche per il trattamento della alcol-dipendenza
ITMI992070A0 (it) Processo per la purificazione di s-adenosil-l-metionina e per la prepa razione dei suoi sali farmaceuticamente accettabili
IT1277897B1 (it) Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
IT1289845B1 (it) Formula per il trattamento della cute e suoi impieghi
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
IT1299069B1 (it) Composizione farmaceutica per il trattamento della "sindrome dolorosa regionale cronica" ("chronic regional pain syndrome crps")
IT1313567B1 (it) Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
IT1306822B1 (it) Calzoncino per il trattamento topico della cellulite.
ITMI932286A0 (it) Procedimento per la preparazione di rufloxacina e suoi sali
ITRM940072A0 (it) Uso della ribonucleasi seminali per la terapia antimetastatica

Legal Events

Date Code Title Description
0001 Granted